Cargando…
Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs’ Revolution for Immunotherapy
Despite several therapeutic advances, malignant melanoma still remains a fatal disease for which novel and long-term curative treatments are needed. The successful development of innovative therapies strongly depends on the availability of appropriate pre-clinical models. For this purpose, several m...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877660/ https://www.ncbi.nlm.nih.gov/pubmed/29534457 http://dx.doi.org/10.3390/ijms19030799 |
_version_ | 1783310743426301952 |
---|---|
author | Barutello, Giuseppina Rolih, Valeria Arigoni, Maddalena Tarone, Lidia Conti, Laura Quaglino, Elena Buracco, Paolo Cavallo, Federica Riccardo, Federica |
author_facet | Barutello, Giuseppina Rolih, Valeria Arigoni, Maddalena Tarone, Lidia Conti, Laura Quaglino, Elena Buracco, Paolo Cavallo, Federica Riccardo, Federica |
author_sort | Barutello, Giuseppina |
collection | PubMed |
description | Despite several therapeutic advances, malignant melanoma still remains a fatal disease for which novel and long-term curative treatments are needed. The successful development of innovative therapies strongly depends on the availability of appropriate pre-clinical models. For this purpose, several mouse models holding the promise to provide insight into molecular biology and clinical behavior of melanoma have been generated. The most relevant ones and their contribution for the advancement of therapeutic approaches for the treatment of human melanoma patients will be here summarized. However, as models, mice do not recapitulate all the features of human melanoma, thus their strengths and weaknesses need to be carefully identified and considered for the translation of the results into the human clinics. In this panorama, the concept of comparative oncology acquires a priceless value. The revolutionary importance of spontaneous canine melanoma as a translational model for the pre-clinical investigation of melanoma progression and treatment will be here discussed, with a special consideration to the development of innovative immunotherapeutic approaches. |
format | Online Article Text |
id | pubmed-5877660 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-58776602018-04-09 Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs’ Revolution for Immunotherapy Barutello, Giuseppina Rolih, Valeria Arigoni, Maddalena Tarone, Lidia Conti, Laura Quaglino, Elena Buracco, Paolo Cavallo, Federica Riccardo, Federica Int J Mol Sci Review Despite several therapeutic advances, malignant melanoma still remains a fatal disease for which novel and long-term curative treatments are needed. The successful development of innovative therapies strongly depends on the availability of appropriate pre-clinical models. For this purpose, several mouse models holding the promise to provide insight into molecular biology and clinical behavior of melanoma have been generated. The most relevant ones and their contribution for the advancement of therapeutic approaches for the treatment of human melanoma patients will be here summarized. However, as models, mice do not recapitulate all the features of human melanoma, thus their strengths and weaknesses need to be carefully identified and considered for the translation of the results into the human clinics. In this panorama, the concept of comparative oncology acquires a priceless value. The revolutionary importance of spontaneous canine melanoma as a translational model for the pre-clinical investigation of melanoma progression and treatment will be here discussed, with a special consideration to the development of innovative immunotherapeutic approaches. MDPI 2018-03-10 /pmc/articles/PMC5877660/ /pubmed/29534457 http://dx.doi.org/10.3390/ijms19030799 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Barutello, Giuseppina Rolih, Valeria Arigoni, Maddalena Tarone, Lidia Conti, Laura Quaglino, Elena Buracco, Paolo Cavallo, Federica Riccardo, Federica Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs’ Revolution for Immunotherapy |
title | Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs’ Revolution for Immunotherapy |
title_full | Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs’ Revolution for Immunotherapy |
title_fullStr | Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs’ Revolution for Immunotherapy |
title_full_unstemmed | Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs’ Revolution for Immunotherapy |
title_short | Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs’ Revolution for Immunotherapy |
title_sort | strengths and weaknesses of pre-clinical models for human melanoma treatment: dawn of dogs’ revolution for immunotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877660/ https://www.ncbi.nlm.nih.gov/pubmed/29534457 http://dx.doi.org/10.3390/ijms19030799 |
work_keys_str_mv | AT barutellogiuseppina strengthsandweaknessesofpreclinicalmodelsforhumanmelanomatreatmentdawnofdogsrevolutionforimmunotherapy AT rolihvaleria strengthsandweaknessesofpreclinicalmodelsforhumanmelanomatreatmentdawnofdogsrevolutionforimmunotherapy AT arigonimaddalena strengthsandweaknessesofpreclinicalmodelsforhumanmelanomatreatmentdawnofdogsrevolutionforimmunotherapy AT taronelidia strengthsandweaknessesofpreclinicalmodelsforhumanmelanomatreatmentdawnofdogsrevolutionforimmunotherapy AT contilaura strengthsandweaknessesofpreclinicalmodelsforhumanmelanomatreatmentdawnofdogsrevolutionforimmunotherapy AT quaglinoelena strengthsandweaknessesofpreclinicalmodelsforhumanmelanomatreatmentdawnofdogsrevolutionforimmunotherapy AT buraccopaolo strengthsandweaknessesofpreclinicalmodelsforhumanmelanomatreatmentdawnofdogsrevolutionforimmunotherapy AT cavallofederica strengthsandweaknessesofpreclinicalmodelsforhumanmelanomatreatmentdawnofdogsrevolutionforimmunotherapy AT riccardofederica strengthsandweaknessesofpreclinicalmodelsforhumanmelanomatreatmentdawnofdogsrevolutionforimmunotherapy |